Hypertension

This page includes news and new technology on hypertension. The condition is caused by abnormally high blood pressure that causes excess force and pressure of the blood against the artery walls. Long-term, this can cause damage the vessels and contributes to heart disease. Therapies include antihypertensive medications such as diurestics  and renal denervation therapy. 

The Record Paradise RDN catheter uses a balloon catheter filled with water to cool the vessel wall as ultrasound-based ablation energy is delivered. It delivers a ring of ablative energy to a depth of 1-6 mm. Kirtane said it requires 2-3 sonications lasting 7 seconds each in each of the main renal arteries. #ACC21 #ACC2021 #RDN

The Record Paradise RDN catheter uses a balloon catheter filled with water to cool the vessel wall as ultrasound-based ablation energy is delivered. It delivers a ring of ablative energy to a depth of 1-6 mm. Kirtane said it requires 2-3 sonications lasting 7 seconds each in each of the main renal arteries.

Feature | Hypertension | May 16, 2021 | By Dave Fornell, Editor
Renal Denervation Lowers Blood Pressure in Medication-Resistant Hypertension 
May 16, 2021 — Two months after undergoing renal denervation (RDN) with the ReCor Paradise renal denervation system,...
read more
SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to treat a variety of hypertensive disorders, announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). The  TIVUS System for renal artery denervation treats resistant hypertension, which is defined as blood pressure that remains above 140/90 mmHg despite use of three antihypertensive medications of different classes at the best tolerated doses.

SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to treat a variety of hypertensive disorders, announced that it has been granted Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA).

News | Renal Denervation | December 09, 2020
FDA Grants Breakthrough Device Designation for the TIVUS Renal Artery Denervation System
December 9, 2020 — SoniVie, an Israeli company developing the Therapeutic Intra-Vascular Ultrasound (TIVUS) System to...
read more
VitalSight is a HIPAA-compliant, Medicare-reimbursable home blood pressure monitoring solution that generally comes at no cost to the patient, depending on their coverage. The kit typically includes a digital blood pressure monitor with cuff, weight scale and digital medication tracker, as well as a data hub.
News | Hypertension | July 15, 2020
Omron and Mount Sinai Health Collaborate to Monitor High-risk Patient Blood Pressure at Home
July 15, 2020 – Omron Healthcare Inc. and Mount Sinai Health System, New York City’s largest academic medical system,...
read more
The Medtronic Symplicity Spyral renal denervation catheter in the renal artery, showing how its four electrodes contact the vessel wall for a single RF energy delivery procedure. By ablating the vessel walls, it props the vessel in a fully open position, allowing the kidneys to better filter the blood and remove excess water in hypertension patients. RDN

The Medtronic Symplicity Spyral renal denervation catheter in the renal artery, showing how its four electrodes contact the vessel wall for a single RF energy delivery procedure. By ablating the vessel walls, it props the vessel in a fully open position, allowing the kidneys to better filter the blood and remove excess water in hypertension patients.

News | Renal Denervation | June 26, 2020
Simplicity Renal Denervation Lowered Blood Pressure Out to 3 Years
June 26, 2020 – New data from the Global SYMPLICITY Registry (GSR) showed that renal denervation (RDN) with the...
read more
Childhood Obesity and High Blood Pressure Warn of Future Heart Disease. Vivian Fornell playing doctor at the Elgin Public Library. Photo by Dave Fornell
News | Hypertension | April 30, 2020
Childhood Obesity and High Blood Pressure Warn of Future Heart Disease
April 30, 2020 — A large study in adolescents and children, some as young as 3 years of age, shows a link between...
read more
ACE and ARBs provide benefit to cardiac patients and harm to COVID-19 patients remains unproven, NEJM
News | Coronavirus (COVID-19) | April 08, 2020
No Evidence Supporting Discontinuing RAAS Inhibitors in COVID-19 Patients
April 8, 2020 — There has been debate in the past month or so during the novel coronavirus (COVID-19) pandemic whether...
read more
News | Renal Denervation | April 01, 2020
Renal Denervation Effective in Patients With Untreated Hypertension
April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had...
read more
News | Renal Denervation | April 01, 2020
Renal Denervation Effective in Patients With Untreated Hypertension
April 1, 2020 — Three months after undergoing renal denervation (RDN), patients with untreated high blood pressure had...
read more
The European Society of Cardiology (ESC) is recommending in novel coronavirus (COVID-19) patients not discontinuing angiotensin converting enzyme inhibitors (ACE-i) or angiotensin receptor blockers (ARBs) used to control hypertension. 
News | Coronavirus (COVID-19) | March 16, 2020 | Dave Fornell, Editor
ESC Council on Hypertension Says ACE-I and ARBs Do Not Increase COVID-19 Mortality
March 16, 2020 — The European Society of Cardiology (ESC) issued a statement March 13 recommending in novel coronavirus...
read more
Aria CV Pulmonary Hypertension System_Aria CV PH System

The Aria CV Pulmonary Hypertension System.

News | Hypertension | February 27, 2020
Aria CV Pulmonary Hypertension Acquires $31 Million for Feasibility Study
February 27, 2020 — Aria CV Inc. completed a $31 million Series B round of financing to fund its first clinical study...
read more
The Aria CV Pulmonary Hypertension System (Aria CV PH System) received FDA Breakthrough Device status.
News | Hypertension | February 07, 2020
Aria CV Receives FDA Breakthrough Designation for Device to Treat Pulmonary Arterial Hypertension
February 7, 2020 — The U.S. Food and Drug Administration (FDA) has granted Breakthrough Device Designation for the Aria...
read more
BackBeat CNT is the flagship therapy of Orchestra BioMed Inc. It is a bioelectronic treatment that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS).

The BackBeat CNT system is a bioelectronic treatment that immediately, substantially and chronically lowers blood pressure (BP) while simultaneously modulating the autonomic nervous system (ANS). 

News | Hypertension | October 10, 2019
MODERATO II Study: Cardiac Neuromodulation Significantly Reduces Systolic Blood Pressure
October 10. 2019 — Late-breaking results from its MODERATO II double-blind, randomized study of BackBeat Cardiac...
read more
Abnormal Blood Pressure in Middle And Late Life Influences Dementia Risk

Image courtesy of the American Heart Association

News | Hypertension | August 20, 2019
Abnormal Blood Pressure in Middle And Late Life Influences Dementia Risk
August 20, 2019 — In a study that spanned two and a half decades and looked at data from more than 4,700 participants,...
read more
FDA Approves Barostim Neo System for Advanced Heart Failure Patients. Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels.

Similar to a pacemaker, the Barostim Neo System uses a pulse generator implanted below the collar bone with a lead that attaches to the carotid artery in the neck. It delivers electrical impulses to baroreceptors in the neck, which sense how blood is flowing through the carotid arteries and relays information to the brain. The brain, in turn, sends signals to the heart and blood vessels that relax the blood vessels and inhibit the production of stress-related hormones to reduce heart failure symptoms.

Technology | Heart Failure | August 19, 2019
FDA Approves Pacemaker-like Device to Treat Heart Failure
August 19, 2019 — The U.S. Food and Drug Administration (FDA) granted market clearance the Barostim Neo System for the...
read more
Blood Pressure Control Less Likely Among Those Treated in Low-income Areas
News | Hypertension | August 14, 2019
Blood Pressure Control Less Likely Among Those Treated in Low-income Areas
August 14, 2019 — People enrolled in a large clinical hypertension management trial were half as likely to control...
read more
© Copyright Wainscot Media. All Rights Reserved.